As of May 29, 2025, Biofrontera AG (B8F.DE) reports a Forward P/E of 72.66.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Biofrontera AG's Forward P/E to Peers
To better understand Biofrontera AG's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Biofrontera AG (B8F.DE) | 72.66 |
| Eurobio Scientific SA (ALERS.PA) | 28.41 |
| Addex Therapeutics Ltd (ADXN.SW) | 11.37 |
| Kancera AB (KAN.ST) | 0.40 |
Compared to its competitors, Biofrontera AG's Forward P/E is higher than all peers, reflecting higher growth expectations from investors.